Kornimate/medical-research-clean huggingface dataset:
prospective assessment of adolescent drinking trajectories with computer-assisted self-administration of ethanol (case)

Conditions: Alcoholism

Summary: the computer-assisted self-administration of ethanol (case)will be administered twice, at the ages 18 and 20, in a prospective study of 80 adolescents living in the dresden area. the sample will be recruited for a differential family history of alcoholism (fha) and gender, with inventories of alcohol use disorder (aud) symptoms and personal recent drinking history (rdh) obtained prior to each case session.


Eligibility criteria:
inclusion criteria: * (a) male and female caucasian volunteers aged 18 years/0 months to 19 years/11 months; * (b) written informed consent by the subject; * (c) habitual social drinking during the two months preceding participation, defined by at least one drinking day in any two weeks-interval; * (d) at least one prior experience of alcohol intoxication * (e) being able to abstain from tobacco use for four hours without developing nicotine withdrawal symptoms; * (f) effective contraception in female participants; * (g) consenting to abstain from any illegal substance use for 2 weeks prior to participation; * (h) living within 15 km (9.5 miles) from downtown dresden; * (i) sufficient information concerning alcohol use in both parents and in at least four second-degree relatives exclusion criteria: * (a) prior medical treatment due to alcohol use; * (b) current or prior history of any serious disease, including cns, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, alcohol or drug dependence, but not alcohol abuse; * (c) current history of axis-i psychiatric illness, including premenstrual dysphoric disorder; * (d) current or prior history of alcohol-induced flushing reactions; * (e) positive urine screen for cannabinoids, cocaine, amphetamines, opiates, or benzodiazepines; * (f) light or non-drinkers: averaging less than 2 standard drinks per week in the preceding two months; * (g) intention to become pregnant * (h) pregnancy or positive urine pregnancy screening or breast-feeding; * (i) any alcohol intake on the test day or the day before; * (k) use of medications known to interact with alcohol within 2 weeks of the study; * (l) positive hepatitis or hiv at screening, provided the subject consented to these tests
memory training in insomnia with cognitive impairment

Conditions: Cognitive Therapy/Methods; Insomnia Chronic; Cognitive Dysfunction

Summary: this randomized controlled trial investigates the effects of cognitive remediation therapy (crt) on chronic insomnia (ci) with mild cognitive impairment.

chronic insomnia (ci) is a prevalent sleep disorder that not only causes night-time sleep difficulties but also impairs daytime functioning and cognitive abilities, including deficits in attention, memory, and executive function. persistent insomnia may diminish the brain's information processing capacity, affecting memory, attention, and decision-making. crt, a structured cognitive training intervention, has been shown in psychiatric populations to enhance memory, attention, and executive function by promoting neuroplasticity, neurotransmitter modulation, and optimizing brain activity patterns. applying crt to ci patients may similarly support cognitive recovery and indirectly improve sleep quality. however, empirical evidence remains limited. this randomized controlled trial will enroll 70 patients with ci and cognitive decline. participants will be randomly assigned to either a crt plus sleep hygiene education (she) group or an she-only group (n=35 each). the crt intervention will last 6 weeks, with daily 50-minute sessions. evaluations will occur at baseline, post-intervention, and at 3, 6, and 12 months follow-up. this study aims to provide evidence for crt as a treatment for ci with cognitive impairment and inform future clinical practices.

Eligibility criteria:
inclusion criteria: 1. meets the diagnostic criteria for insomnia disorder according to dsm-5. 2. pittsburgh sleep quality index (psqi) total score \> 5. 3. age ≥ 8 years. 4. voluntary participation with signed informed consent. 5. meets the cognitive impairment criteria associated with ci: (1) right-handedness. (2) age between 55 and 75 years. (3) education duration ≥ 12 years. (4) at least junior high school education level; fulfills petersen's diagnostic criteria for mild cognitive impairment: 1.subjective complaints of memory decline. 2.duration of cognitive complaints ≥ 3 months. 3.assessment scores: global deterioration scale (gds) rating of stage 1-2; clinical dementia rating (cdr) score of 0-0.5. 4.memory test scores falling ≥ 1.5 standard deviations below the age- and education-matched norms: mmse ≥ 24, moca \ 26. 5.memory impairment as the primary deficit, with relatively preserved functioning in other cognitive domains. 6.normal daily functional abilities. 7.exclusion of dementia or any major physical or psychiatric disorders that could impair brain function. exclusion criteria: 1. presence of severe physical illnesses or major psychiatric disorders, or assessed risk of suicide. 2. diagnosed or suspected sleep breathing disorders, restless legs syndrome, circadian rhythm sleep disorders, or currently engaged in shift work. 3. pregnancy or breastfeeding. 4. currently undergoing any form of psychological therapy. 5. history of infectious diseases such as syphilis or hiv.
hemoglobin concentration in patients with an acute respiratory distress syndrome

Conditions: ARDS, Human

Summary: retrospective analysis of hemoglobin concentrations and red cell transfusion thresholds in patients with an acute respiratory distress syndrome (ards) admitted to an ards-center of a german university hospital.

transfusion of packed red blood cells is a common procedure in critically ill patients. in recent years it has been shown that for many patient populations a restrictive transfusion strategy is not inferior compared to a liberal transfusion strategy with regard to overall outcome. so far it is unclear whether patients with an ards should receive blood transfusions according to a restrictive or liberal transfusion strategy. besides pulmonary gar exchange and cardiac output, the hemoglobin concentration is an important determinant for oxygen delivery. the aim of this retrospective observational study is to analyze if low levels of hemoglobin/a restrictive transfusion strategy and are associated with a different mortality compared to higher levels of hemoglobin/a liberal transfusion strategy in patients with an ards.

Eligibility criteria:
inclusion criteria: * all adult patients with ards * admission to the charité ards center exclusion criteria: * all patients \<18 years at the time of admission * all patients with ards not admitted to the charité ards center
study of cardiac mri in patients with left-sided breast cancer receiving radiation therapy

Conditions: Breast Cancer

Summary: this is a pilot study to determine if there are changes in heart function following completion of radiation therapy for breast cancer as measured by cardiac magnetic resonance imaging (cardiac mri) scans. additional purposes of this study are to assess cardiac side effects from radiation treatment, evaluate cardiac mri changes by radiation technique, and compare quality of life questionnaires.

as part of this study, participants will have a cardiac mri at baseline and a follow-up cardiac mri within 1 year after completion of standard radiation therapy for left-sided breast cancer. the cardiac mri scans will be evaluated to determine if there are changes in cardiac function within 1 year after radiation treatment. patients will be asked to complete a questionnaire before and after treatment that asks about their health and any symptoms they may be having. physical exams and any other standard of care service or treatment will be at the discretion of the treating physician.

Eligibility criteria:
inclusion criteria: * left-sided breast cancer stage i-iii. * indications for adjuvant regional nodal and breast or chest wall radiation therapy (rt). * women and men are allowed. * must be at least 18 years old at time of consent. exclusion criteria: * pregnant and/or breastfeeding women or patients of child-producing potential not willing to use contraception while on study. * prior history of cardiovascular disease per physician discretion. * stage 0 and iv breast cancer. * prior radiation therapy to chest. * concurrent trastuzumab per physician discretion.

Keywords: cardiac mri radiation proton radiation breast cancer
effect of chicory-derived inulin on abdominal sensations and bowel motor function

Conditions: Functional Gastrointestinal Disorders

Summary: subjects with gas-related complaints exhibit impaired handling of intestinal gas loads and we hypothesized that inulin would have a beneficial effect. aim: to determine the effect of a prebiotic chicory-derived inulin-type fructan on the tolerance of intestinal gas. methods. placebo-controlled, parallel, randomized and double-blind trial study. subjects with abdominal symptoms and reduced tolerance of intestinal gas (selected by a pre-test) will receive either inulin (8 g/d, n=18) or maltodextrin as a placebo (8 g/d, n=18) for 4 wk. a gas challenge test (4 h jejunal gas infusion at 12 ml/min while measuring abdominal symptoms and gas retention for 3 h) will be performed before and at the end of the intervention phase. gastrointestinal symptoms and bowel habits (using daily questionnaires for 1 wk) and fecal bifidobacteria counts will be measured before and at the end of the intervention.


Eligibility criteria:
inclusion criteria: * negative sensation of digestive well-being (score ≤ 1 on at least 2 of the 6 evaluation days, scored on a - 5 / +5 scale. * poor tolerance of a gas challenge test (abdominal perception score ≥ 3, on a 0-6 scale, for at least three 15-min time points over the last 90 minutes of the 180-minute-long intestinal gas infusion test). exclusion criteria: * antibiotic intake, * exceptional diets, * changes in dietary habits or intake of ca supplements over the preceding month.

Keywords: intestinal gas functional gut symptoms intestinal sensitivity intestinal motility
transbronchial lung cryobiopsy in undiagnosed acute respiratory failure

Conditions: Acute Respiratory Failure; Acute Respiratory Distress Syndrome

Summary: in patients with acute hypoxemic respiratory failure whose diagnosis is not established after initial evaluation, obtaining a histopathological diagnosis may improve the patients' prognosis. in our previous retrospective-controlled study, transbronchial lung cryobiopsy (tblc) can lead to an increased chance of establishing a diagnosis compared with transbronchial lung biopsy (tblb), with an acceptable safety profile. therefore, further prospective randomized controlled studies exploring whether tblc leads to improved prognosis for such patients are warranted.


Eligibility criteria:
inclusion criteria: 1. diagnosis of acute hypoxemic respiratory failure 2. routine assessments \[including bronchoscopy, bronchoalveolar lavage fluid cytology and pathogenic (including pathogenic mngs) tests, blood tests, etc.\] do not clarify the etiology, or there is an unexplained disease process 3. imaging shows a multi-lobar segmental distribution of ground glass opacity with or without consolidations 4. patients' families agreed to participate in the study and signed an informed consent form exclusion criteria: 1. significant hemodynamic instability 2. uncorrectable coagulopathy 3. severe pulmonary hypertension 4. acute coronary syndrome 5. intermediate-high-risk acute pulmonary embolism 6. acute phase of stroke 7. severe emphysema 8. aortic dissection and massive gastrointestinal bleeding 9. other conditions that are not suitable for participation in the clinical trial
impact of ldl-cholesterol lowering on platelet activation

Conditions: Familial Hypercholesterolemia

Summary: the primary goal is to assess the impact of evolocumab therapy on platelet function of familial hypercholesterolemia (fh) patients in a randomized, double blind study. evolocumab is a humanized monoclonal antibody that targets circulating pcsk9, increases hepatic ldl receptor, decreases plasma ldl cholesterol and reduces risk of cardiovascular events. evolocumab (brand name rapatha) has been approved by fda along with diet and maximally tolerated statin therapy in adults with fh or atherosclerotic heart or blood vessel problems, who need additional lowering of ldl cholesterol. the secondary goal is to determine if platelet activation or the response to evolocumab therapy is modified by rs3184504 polymorphism. the investigators believe that these investigations will complement ongoing studies to demonstrate that evolocumab reduces athero-thrombotic risk and aid the decision-making as to whether evolocumab can reduce the atherothrombotic risk in acute coronary syndrome (acs) patients.

hyperlipidemia as exemplified by familial hypercholesterolemia is associated with increased platelet activation and an underlying pro-coagulant state. hyperlipidemia primes platelets and increases platelet activation in response to various agonists. plasma cholesterol levels appear to have a critical role in modulating platelet activity as hypercholesterolemia increases platelet activation more potently than hypertriglyceridemia. increased platelet reactivity may contribute to the increased risk of atherothrombosis associated with hypercholesterolemia. plasma levels of platelet activation markers such as thrombin-antithrombin complex (tat), soluble p-selectin (sp-selectin), soluble cd40l (scd40l) or p-selectin exposure at surface of platelets are increased in hypercholesterolemic patients. increased levels of the platelet activation markers are associated with increased platelet membrane cholesterol content in hypercholesterolemia.statins may show antithrombotic properties.

Eligibility criteria:
inclusion criteria: * subjects who have a clinical diagnosis of familial hypercholesterolemia (fh) * subjects who are referred to dr. ginsberg's lipid practice for treatment with pcsk9 inhibitor * subjects with ldl cholesterol levels \>100 mg/dl on baseline treatment with statins and/or ezetimibe exclusion criteria: * children under 18 years of age

Keywords: hyperlipidemia, hypercholesterolemia, atherothrombosis
proteomics for chronic disorder of consciousness

Conditions: Disorder of Consciousness

Summary: following severe traumatic brain injury, patients may remain unconscious for many years. it is the first proteomic analysis comparing differentially expressed proteins between patients with chronic disorder of consciousness and controls so far. the investigators generated accurate lists of proteomes and identified differences at different disease time courses. the obtained results provide new insight into understanding the molecular mechanisms underlying the chronic disorder of consciousness.

background: patients who awake from severely traumatic brain injury (stbi) may remain unconscious for many years. although behavioral assessment and functional imaging are currently used as diagnostic tools, the molecular basis underlying chronic condition has yet to be explored. objective:to explore the molecular basis and identify novel biomarkers for the diagnosis and prognosis of patients with chronic disorder of consciousness. method: plasma samples were obtained from patients with chronic disorder of consciousness, and healthy volunteers. a coupled isobaric tag for relative and absolute quantitation (itraq)-based proteomics approach was used to screen differentially expressed proteins (deps) between patients and controls. potential molecular mechanisms were further discussed through bioinformatics analyses. candidate proteins were validated by enzyme-linked immunosorbent assay (elisa).

Eligibility criteria:
inclusion criteria: 1. patients ages 14 to 65 years old; 2. patients had a history of stbi; 3. patients had awakened from a coma (indicating preserved sleep-wake cycles), including vegetative state and minimally consciousness state; 4. patients stay unconscious for more than 1 month. exclusion criteria: 1. patients with acute infectious diseases or liver dysfunction; 2. patients with serious diseases such as cardiac or pulmonary problems.

Keywords: proteomics plasma chronic disorder of consciousness
prognostic value of rxr-α in cutaneous squamous and basal cell carcinoma

Conditions: Non-melanoma Skin Cancer

Summary: vitamin d has a crucial role in cancer control and prevention.vitamin d receptor (vdr) and its heterodimer retinoid x receptor (rxr) are equally important in the cell. this ligand (vitamin d) and receptors (vdr-rxr) complex together triggers downstream dna damage response in the cell. retinoid receptors are a superfamily of nuclear receptors. the preferred receptor that attaches to vdr is rxr, with its subunits α, β and γ. rxr α is more frequent in the skin than other tissues, while β occurs in internal organs and γ is frequently related to neural disorders. the investigator hopes to assess prognosis of scc \& bcc by using rxr-α biomarker \& attempts to use it in the treatment.


Eligibility criteria:
inclusion criteria: 1. squamous cell carcinoma and basal cell carcinoma. 2. incisional \& excisional biopsies. 3. all the studied cases include sufficient materials for the immunohistochemical study 4. complete clinical data exclusion criteria: 1. patients with a history of preoperative chemotherapy and/or radiotherapy. 2. insufficient or tiny tissue biopsies.
east-west collaboration treatment using bee venom acupuncture and nsaids for chronic cervicalgia

Conditions: Chronic Non-specific, Uncomplicated Neck Pain

Summary: the purpose of this study is to evaluate the efficacy and safety of east-west collaborative treatment using bee venom acupuncture and nsaids on pain intensity, functional status and quality of life of patients with chronic cervicalgia


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * nonspecific, uncomplicated, chronic neck pain over 3 months * volunteer can read and write in korean, providing written informed consent exclusion criteria: * exhibited abnormalities on neurological examination * radicular pain * serious spinal disorders including malignancy, vertebral fracture, spinal infection or inflammatory spondylitis * other chronic diseases that could affect or interfere with the therapeutic outcomes including cardiovascular disease, diabetic neuropathy, active hepatitis, fibromyalgia, rheumatoid arthritis, dementia or epilepsy * previous spinal surgery or scheduled procedures during the study * painful conditions induced by traffic accidents * a substantial musculoskeletal problem generating pain from an area other than the neck * conditions for which administration of bva might not be safe including clotting disorders, administration of an anticoagulant agent, pregnancy and seizure disorders * a documented hypersensitive reaction to previous bva treatments, bee stings or insect bites * positive reaction observed during a skin hypersensitivity test * severe psychiatric or psychological disorders * current use of corticosteroids, narcotics, muscle relaxants or herbal medicines to treat neck pain or any medication considered inappropriate by the investigator * pending lawsuits or receipt of compensation due to neck pain.

Keywords: chronic neck pain combined treatment between conventional and complementary alternative medical treatment bee venom acupuncture nsaids
efficacy and safety of a purified standardised wasp venom preparation

Conditions: Allergy

Summary: the trial is performed to assess efficacy and safety of a purified standardised wasp venom preparation in wasp venom allergy


Eligibility criteria:
inclusion criteria: * history of wasp venom allergy, * positive rast to wasp venom, * positive skin prick test to wasp venom exclusion criteria: * serious chronic diseases

Keywords: wasp venom allergy, specific immunotherapy
the impact of artificial intelligence dietary smartphone application on nutritional status among cancer patients

Conditions: Malnutrition, Calorie; Malnutrition; Protein; Weight Change, Body

Summary: multi-center prospective pilot trial study

this is a clinical study to evaluate impact of dietary smartphone application on nutritional status among cancer patients. the study hypotheses there is improvement in nutritional outcome in intervention group if compare with control group. the eligible subjects will be screened according to inclusion criteria and approached individually to participate in this study. the consented subjects will be divided randomly into two groups, intervention and conventional groups. conventional dietitian care will be given to conventional group (cg) while intervention group (ig) will received innovated dietitian care where they will be introduced with idsa apps and installed in consented subjects' smartphone. all subjects will be reviewed again by dietitian in 1-month time to assess nutritional status (weight and energy protein intake) as well as nutrition impact symptoms.

Eligibility criteria:
inclusion criteria: * possessing smartphone and is willing to use smartphone application * been referred to dietitian in outpatient clinic * at least 18 years of age * malaysian exclusion criteria: * inability to use the smartphone application (eg. due to vision problems) * not been referred to dietitian in outpatient clinic * patients who participate in other study at the same time * on nutrition support (enteral / intra-venous) * vulnerable subjects

Keywords: artificial intelligence dietary application weight oral intake
ion channel genetic biomarkers: diagnostic capabilities in the assessment of bipolar disorder

Conditions: Bipolar Disorder

Summary: genotype 164 adults to evaluate six selected single nucleotide polymorphisms (snps) (rs1006737, rs10994336, rs10994133, rs2238071, rs1051375, rs1024582) for use as a genetic biomarker to differentiate between bipolar depression and unipolar depression.

adults ages 18-80 will be recruited if they are diagnosed with bipolar disorder, major depression, or have no mood symptoms. the adults will undergo a diagnostic interview, the mini international neuropsychiatric interview (mini) for the diagnosis. the subjects will also complete the adverse childhood events scale to evaluate for a genetic x environmental interaction in detecting bipolar disorder at initial assessment. genotyping will be done by snapshot genotyping method and genetic sample will be collected via buccal swab.

Eligibility criteria:
inclusion criteria: * presenting to one of 4 denver metro area clinics * subjects must fall into one of 3 diagnostic categories, bipolar, mdd, or no mood symptoms. exclusion criteria: * inability to provide informed consent * history of tbi * history of untreated seizure disorder * substance abuse in the last 8 hours * moderate-severe substance abuse disorder diagnosed in the last 6 months
pilot phase for an acute evaluation of a non-implantable electrical continence device

Conditions: Urinary Bladder, Overactive

Summary: the purpose of this feasibility clinical investigation is to investigate a new medical device treatment for overactive bladder (oab) in women.

the fempulse system is a vaginal ring intended to provide mild electrical stimulation to nerves that regulate bladder function. it is believed that stimulation of these nerves may help relieve the symptoms of oab.

Eligibility criteria:
inclusion criteria: * normal healthy women ≥ 21 years old * using contraception if of reproductive age exclusion criteria: * pregnant, recently pregnant or actively trying to conceive * prior hysterectomy * current or recent urinary tract or vaginal infection

Keywords: overactive bladder women neuromodulation bioelectronic medicine